APRE (STOCKS)
Aprea Therapeutics, Inc. Common stock
$0.606400
-0.033600 (-5.25%)
Prev close: $0.640000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Oren Gilad
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4.25M
- Employees
- 8
- P/E (TTM)
- -0.30
- P/B (TTM)
- 0.35
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.47 | $-0.35 | -0.1247 | -36.11% |
|
Jun 2025 (Q2)
|
$-0.53 | $-0.76 | +0.2299 | +30.25% |
|
Dec 2024 (Q4)
|
$-0.49 | $-0.70 | +0.2104 | +30.04% |
|
Sep 2024 (Q3)
|
$-0.64 | $-0.76 | +0.1199 | +15.78% |
Financial Statements
| Revenues | $488.24K |
| Benefits Costs and Expenses | $13.53M |
| Costs And Expenses | $14.31M |
| Operating Expenses | $14.31M |
| Operating Income/Loss | -$13.82M |
| Income/Loss From Continuing Operations After Tax | -$13.04M |
| Income/Loss From Continuing Operations Before Tax | -$13.04M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$13.04M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$13.04M |
| Net Income/Loss Available To Common Stockholders, Basic | -$13.04M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.12 |
| Diluted Earnings Per Share | -$2.22 |
| Basic Average Shares | 6,300,775 |
| Diluted Average Shares | 6,300,775 |
| Assets | $14.32M |
| Current Assets | $13.94M |
| Noncurrent Assets | $377.33K |
| Fixed Assets | $65.24K |
| Other Non-current Assets | $312.09K |
| Liabilities | $3.41M |
| Current Liabilities | $2.68M |
| Accounts Payable | $641.32K |
| Wages | $588.79K |
| Other Current Liabilities | $1.45M |
| Noncurrent Liabilities | $727.36K |
| Equity | $10.91M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $10.91M |
| Liabilities And Equity | $14.32M |
| Net Cash Flow From Operating Activities | -$13.44M |
| Net Cash Flow From Operating Activities, Continuing | -$13.44M |
| Net Cash Flow From Investing Activities | $9.13M |
| Net Cash Flow From Investing Activities, Continuing | $9.13M |
| Net Cash Flow From Financing Activities | $933.07K |
| Net Cash Flow From Financing Activities, Continuing | $933.07K |
| Net Cash Flow | -$3.38M |
| Net Cash Flow, Continuing | -$3.38M |
| Comprehensive Income/Loss | -$13.06M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$13.06M |
| Other Comprehensive Income/Loss | -$24.79K |